Search results for "Visual Acuity"

showing 10 items of 456 documents

Surgical management of acute angle-closure glaucoma after toric implantable contact lens implantation

2006

A case of pupillary block after implantation of an implantable contact lens (ICL) is reported, and surgical management and prevention are discussed. In a myopic patient, the best corrected visual acuity in the right eye was 20/50 with -15.50 -3.00 x 175. After uneventful implantation of an ICL, painful acute glaucoma developed with an intraocular pressure beyond measurable values. Apparent anterior vaulting of the ICL suggested a sizing problem. In a situation of a mid-wide dilated pupil, immediate explantation of the ICL was performed. Then, using a preoperative iris photography as guidance, an anterior chamber iris-claw toric phakic intraocular lens was implanted. On postoperative examina…

Reoperationmedicine.medical_specialtyIntraocular pressuregenetic structuresContact LensesVisual AcuityPhakic intraocular lensPupilLens Implantation IntraocularOphthalmologyMyopiamedicineHumansIris (anatomy)Device RemovalIntraocular PressurePupillary blockbusiness.industryeye diseasesSensory SystemsSurgeryOphthalmologymedicine.anatomical_structureIris DiseasesAcute angle-closure glaucomaImplantable Contact LensLens (anatomy)Acute DiseaseSurgerysense organsGlaucoma Angle-ClosurebusinessJournal of Cataract and Refractive Surgery
researchProduct

Keratoconus apex positions impact on visual acuity and contrast sensitivity

2020

The change of corneal shape in keratoconus subjects can impact the optical quality of the eye on the retina and it reduces the contrast sensitivity by light scattering. The aim of our study was to estimate the keratoconus subjects’ contrast sensitivity and visual acuity depending on keratoconus apex position. We included 45 keratoconus subjects (77 eyes), which have keratoconus in the first to the third stage, in our study. There were 33 eyes with keratoconus apex in the central part of the cornea and 46 eyes with keratoconus apex in the periphery of the cornea. Contrast sensitivity and visual acuity were measured at 3 m with and without the best possible spectacle correction using the FrAC…

RetinaKeratoconusmedicine.medical_specialtyVisual acuitygenetic structuresbusiness.industrymedia_common.quotation_subjectmedicine.diseaseeye diseasesOptical qualityApex (geometry)medicine.anatomical_structureCorneaOphthalmologyMedicineContrast (vision)sense organsmedicine.symptombusinessSensitivity (electronics)media_commonBiomedical Spectroscopy, Microscopy, and Imaging
researchProduct

Evidence of neuroplasticity in the human visual cortex following beneficial anti-VEGF treatment in exudative age-related macular degeneration

2012

Purpose Anti-vascular endothelial growth factor (VEGF) agents have been shown to improve visual acuity and prevent vision loss in exudative age-related macular degeneration (AMD). As the vision improves relatively quickly in response to intravitreal injections, we wanted to know whether this improvement is reflected in electrophysiolocal markers of visual cortical processing. Methods Our interventional case series included 6 elderly patients who underwent injection treatment to the affected eye. Their visual acuity, tomographic images of retinal thickness and visual evoked potentials (VEP) were assessed before of the treatment and six weeks after the last injection. Results All patients sho…

Retinamedicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryRetinalGeneral MedicineMacular degenerationAudiologymedicine.diseaseExudative age-related macular degenerationeye diseasesOphthalmologychemistry.chemical_compoundmedicine.anatomical_structureVisual cortexchemistryOphthalmologyNeuroplasticityMedicinesense organsAnti vegf treatmentmedicine.symptombusinessActa Ophthalmologica
researchProduct

Prevalence of early and late age-related macular degeneration in India: the INDEYE study.

2010

Purpose.: To estimate the prevalence of early and late age-related macular degeneration (AMD) in India. Methods.: Of 7518 people aged 60 years and older identified from randomly sampled villages in North and South India, 5853 (78%) attended an eye examination including fundus photography. Fundus images were graded according to the Wisconsin Age-Related Maculopathy Grading System. Results.: Fundus images were ungradable in 1587 people, mainly because of cataract. People 80 years of age and older were less likely to attend the eye examination and more likely to have ungradable images. For ages 60 to 79 years, the percent prevalence (95% confidence interval [CI]) were late AMD 1.2 (0.8–1.5); a…

Rural Populationmedicine.medical_specialtyUrban Populationgenetic structuresVisual AcuityPrevalenceIndiaDiagnostic Techniques OphthalmologicalDrusenFundus (eye)Macular DegenerationAge DistributionOphthalmologyEpidemiologyPrevalencemedicineHumansSex DistributionAgedAged 80 and overmedicine.diagnostic_testbusiness.industryFundus photographyArticlesMiddle AgedMacular degenerationmedicine.diseaseeye diseasesEye examinationMaculopathysense organsbusiness
researchProduct

Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes

2021

Monoclonal gammopathy of ocular significance (MGOS) is a rare subset of monoclonal gammopathy of clinical significance occurring secondary to plasma cell disorders and causing ocular manifestations. We identified 23 patients with paraproteinemic keratopathy (PPK) in the setting of monoclonal gammopathy of unknown significance (MGUS, 10), smoldering multiple myeloma (SMM, 3) or multiple myeloma (MM, 10). Many of these patients with PPK (11/23) presented decreased vision. All patients with MM and 40% of those with other diagnoses such as SMM and MGUS received systemic therapy with or without autologous stem cell transplantation. Four eyes of four patients were treated by penetrating keratopla…

Smoldering Multiple MyelomaCancer Researchmedicine.medical_specialtyVisual acuitygenetic structuresMonoclonal gammopathy of clinical significancemonoclonal gammopathy of ocular significanceTreatment outcomeParaproteinemiasPlasma cellMonoclonal Gammopathy of Undetermined SignificanceTransplantation AutologousSystemic therapyGastroenterologyMonoclonal gammopathy of clinical significance; monoclonal gammopathy of ocular significance; multiple myeloma; paraproteinemic keratopathyCorneal DiseasesAutologous stem-cell transplantationhemic and lymphatic diseasesInternal medicinemedicineHumansClinical significanceMultiple myelomabusiness.industryHematopoietic Stem Cell TransplantationHematologymedicine.diseaseeye diseasesMonoclonal gammopathyparaproteinemic keratopathyTreatment Outcomemedicine.anatomical_structureOncologyNeoplasm Recurrence Localmedicine.symptomMultiple MyelomabusinessLeukemia & Lymphoma
researchProduct

Systemische fibrinolytische Therapie mit Urokinase bei Zentralarterienverschluss der Netzhaut

2005

BACKGROUND AND OBJECTIVE Systemic fibrinolysis has become an important therapeutical option in patients with thrombotic occlusion of coronary or pulmonary arteries. In view of the hemorrhagic risk systemic fibrinolytic therapy for retinal vessel occlusion has been discussed controversial. In the present case study results and complications of systemic fibrinolysis should be investigated in patients with central retinal artery occlusion. PATIENTS AND METHODS From 1995 to 2002 a case series of 19 consecutive patients (8 female, 11 male, age: 63.2+/-14,3 years) with central retinal artery occlusion were treated by systemic application of urokinase using a standardized scheme. The latency from …

Urokinasemedicine.medical_specialtyVisual acuitybusiness.industrymedicine.medical_treatmentGeneral MedicineThrombophiliamedicine.diseaseSurgeryFibrinolysisOcclusionmedicineCentral retinal artery occlusionMedical historyHemorrhagic riskmedicine.symptombusinessmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPI…

2017

Purpose: To assess the effect of topical antibiotic prophylaxis on postoperative endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.Methods: A systematic literature search was performed from inception to March 2016 using PubMed, Medline, Web of Science, Embase, and the Cochrane Library, to identify articles that reported cases of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. We used a pooled analysis to estimate the incidence of cases of endophthalmitis who developed after injections performed with and without topical antibiotic prophylaxis. We used regression analysis to explore the effects of stu…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyEye InfectionsVisual AcuityAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection;Angiogenesis InhibitorsCochrane LibraryGlobal HealthEye Infections Bacteriallaw.invention03 medical and health sciencestopical antibiotic prophylaxis; postoperative endophthalmitis; anti–vascular endothelial growth factor agents; intravitreal injectionpostoperative endophthalmitis0302 clinical medicineEndophthalmitisRandomized controlled triallawtopical antibiotic prophylaxisanti–vascular endothelial growth factor agentsInternal medicinemedicineantibiotic prophylaxiHumansanti-vascular endothelial growth factor030212 general & internal medicineAntibiotic prophylaxisProspective cohort studyAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection; Angiogenesis Inhibitors; Anti-Bacterial Agents; Endophthalmitis; Eye Infections Bacterial; Global Health; Humans; Intravitreal Injections; Vascular Endothelial Growth Factor A; Antibiotic Prophylaxis; Visual AcuityEndophthalmitisbusiness.industryIncidence (epidemiology)Bacterialintravitreal injectionRetrospective cohort studyGeneral MedicineEye infectionAntibiotic Prophylaxismedicine.diseaseAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection; Angiogenesis Inhibitors; Anti-Bacterial Agents; Endophthalmitis; Eye Infections; Bacterial; Global Health; Humans; Intravitreal Injections; Vascular Endothelial Growth Factor A; Antibiotic Prophylaxis; Visual AcuitySurgeryAnti-Bacterial AgentsOphthalmologyendophthalmitiIntravitreal Injections030221 ophthalmology & optometryAnti–vascular endothelial growth factorbusiness
researchProduct

Intravitreal dexamethasone implant versus anti-vascular endothelial growth factor therapy combined with cataract surgery in patients with diabetic ma…

2021

Objective: to compare outcomes of cataract surgery combined with either anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy or dexamethasone implant (DEX) in patients with diabetic macular oedema (DMO). Methods: Pubmed and Embase databases were searched for studies reporting outcomes of diabetic cataract surgery combined with either anti-VEGF or DEX, with a follow-up ≥3 months. The primary outcome was the mean change in central macular thickness (CMT). Mean change in best corrected visual acuity (BCVA) was considered as a secondary outcome. The mean difference between baseline and post-treatment values (MD) with 95%-Confidence Interval (95%CI) was calculated and meta-analyses were p…

Vascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresmedicine.medical_treatmentVisual AcuityEndothelial Growth FactorsMacular EdemaDexamethasoneCataractOphthalmologyDiabetes MellitusHumansMedicineIn patientDexamethasoneDiabetic Retinopathybusiness.industryDEXcataract surgeryCataract surgeryDiabetic cataractBevacizumabOphthalmologyAnti–vascular endothelial growth factor therapyDiabetic macular oedemaanti-VEGFdiabetic macular oedemaMeta-analysissense organsImplantbusinessmedicine.drugEye
researchProduct

Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis

2020

Purpose: To compare efficacy of treat and extend (T&E) versus fixed regimen treatment protocols in neovascular age-related macular degeneration (nAMD). Methods: Randomized clinical trials (RCTs) comparing T&E versus fixed regimen protocols for nAMD were systematically searched. Primary outcome was to compare the mean best corrected visual acuity (BCVA) change in T&E regimen versus fixed regimen. Secondary outcomes were change in the mean optical coherence tomography (OCT) central retinal thickness (CRT) and mean number of injections. Standardized mean difference (SMD) along with 95% confidence intervals (CIs) were calculated. Random-effect models were used for meta-analyses. Res…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyretinaretinal pathology/researchVisual AcuityAngiogenesis InhibitorsTreat and extendlaw.inventionMacular DegenerationRandomized controlled trialClinical Protocolsretina – medical therapieslawInternal medicineAge relatedRanibizumabMedicineHumansbusiness.industryAge-related macular degenerationGeneral MedicineMacular degenerationpediatric ophthalmologyretina – medical therapiemedicine.diseaseOphthalmologyRegimenTreatment OutcomeMeta-analysisvitreous/retinal diseaseIntravitreal InjectionsWet Macular DegenerationPediatric ophthalmologypharmacologybusinessTomography Optical CoherenceAge-related macular degeneration; pediatric ophthalmology; pharmacology; retina; retina – medical therapies; retinal pathology/research; vitreous/retinal disease
researchProduct

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections

2022

Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3 neovascularization in neovascular age-related macular degeneration (nAMD), evaluated by optical coherence tomography angiography (OCTA). Materials and Methods: This is a bicentric retrospective case series. Patients with newly diagnosed type 3 MNV treated with brolucizumab IVI and at least 6 months follow-up were enrolled. OCTA en face images and B-scans were analyzed for lesions at baseline, 1 m…

Vascular Endothelial Growth Factor Atype 3 neovascularization.brolucizumabNeovascularization PathologicVisual Acuityneovascular age-related macular degeneration; type 3 neovascularization; retinal angiomatous proliferation; brolucizumab; optical coherence tomography angiography; intravitreal injectionintravitreal injectionretinal angiomatous proliferationEndothelial Growth Factorsneovascular age-related macular degenerationGeneral MedicineAntibodies Monoclonal Humanizedoptical coherence tomography angiographyIntravitreal InjectionsHumansFluorescein AngiographyTomography Optical CoherenceRetrospective StudiesMedicina
researchProduct